ATE348635T1 - Injizierbare depotformulierung enthaltend iloperidonkrystalle - Google Patents

Injizierbare depotformulierung enthaltend iloperidonkrystalle

Info

Publication number
ATE348635T1
ATE348635T1 AT03756455T AT03756455T ATE348635T1 AT E348635 T1 ATE348635 T1 AT E348635T1 AT 03756455 T AT03756455 T AT 03756455T AT 03756455 T AT03756455 T AT 03756455T AT E348635 T1 ATE348635 T1 AT E348635T1
Authority
AT
Austria
Prior art keywords
crystals
formulation containing
size
deposit formulation
injectable deposit
Prior art date
Application number
AT03756455T
Other languages
English (en)
Inventor
Dierk Wieckhusen
Alexandra Glausch
Markus Ahlheim
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9940486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE348635(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE348635T1 publication Critical patent/ATE348635T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
AT03756455T 2002-07-15 2003-07-14 Injizierbare depotformulierung enthaltend iloperidonkrystalle ATE348635T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0216416.8A GB0216416D0 (en) 2002-07-15 2002-07-15 Organic compounds

Publications (1)

Publication Number Publication Date
ATE348635T1 true ATE348635T1 (de) 2007-01-15

Family

ID=9940486

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03756455T ATE348635T1 (de) 2002-07-15 2003-07-14 Injizierbare depotformulierung enthaltend iloperidonkrystalle

Country Status (16)

Country Link
US (5) US20050250813A1 (de)
EP (1) EP1523335B1 (de)
JP (2) JP5392961B2 (de)
AT (1) ATE348635T1 (de)
AU (1) AU2003281154B2 (de)
CA (1) CA2492467C (de)
CY (1) CY1106305T1 (de)
DE (1) DE60310564T2 (de)
DK (1) DK1523335T3 (de)
ES (1) ES2279153T3 (de)
GB (1) GB0216416D0 (de)
HK (1) HK1076029A1 (de)
NZ (1) NZ537598A (de)
PT (1) PT1523335E (de)
WO (1) WO2004006886A2 (de)
ZA (1) ZA200410323B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60238780D1 (de) 2001-10-30 2011-02-10 Novartis Ag Depot formulierungen von iloperidone und einem sternförmigen polymer
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
EP1675573B2 (de) 2003-10-23 2012-06-13 Otsuka Pharmaceutical Co., Ltd. Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
ES2825949T3 (es) 2004-09-30 2021-05-17 Vanda Pharmaceuticals Inc Métodos para administrar iloperidona
JP2009538331A (ja) 2006-05-22 2009-11-05 ヴァンダ ファーマシューティカルズ インコーポレイテッド 抑うつ障害のための治療
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
PT2170279T (pt) 2007-07-31 2018-04-06 Otsuka Pharma Co Ltd Métodos para produção de suspensão de aripiprazole e formulação liofilizada
JP5653753B2 (ja) 2007-09-10 2015-01-14 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｓｎｐ遺伝子型に基づくｑｔ延長の予測
MX2010006521A (es) 2007-12-13 2010-08-10 Vanda Pharmaceuticals Inc Metodo y composicion para el tratamiento de una condicion mediada por el receptor de serotonina.
US8729100B2 (en) 2007-12-13 2014-05-20 Vanda Pharmaceuticals, Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
WO2010031497A1 (en) * 2008-09-19 2010-03-25 Miklos Vertessy New process for the preparation of iloperidone
CN101822673B (zh) * 2009-03-04 2013-09-18 北京德众万全药物技术开发有限公司 一种含有伊潘立酮的固体药物组合物
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
WO2011032404A1 (zh) 2009-09-19 2011-03-24 浙江华海药业股份有限公司 伊潘立酮的一种制备方法及结晶方法
CN102030744B (zh) * 2009-09-30 2013-04-17 天津药物研究院 伊潘立酮晶体、其制备方法及药物组合物
WO2011055188A1 (en) * 2009-11-05 2011-05-12 Orchid Chemicals And Pharmaceuticals Limited An improved process for the preparation of iloperidone
MX2012007365A (es) * 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
CN102108081A (zh) * 2009-12-25 2011-06-29 重庆医药工业研究院有限责任公司 伊潘立酮的新晶型及其制备方法
EP2523669B1 (de) 2010-01-11 2016-12-07 Inotek Pharmaceuticals Corporation Kombination, kit und verfahren zur reduzierung des augeninnendrucks
MX2012010724A (es) 2010-03-26 2012-11-12 Inotek Pharmaceuticals Corp Metodo para reducir la presion intraocular en seres humanos empleando n6-ciclopentiladenosina (cpa), derivados de cpa o profarmacos de los mismos.
CN101822674B (zh) * 2010-05-27 2015-03-11 北京德众万全医药科技有限公司 一种伊潘立酮药物组合物及其制备方法
CN107595771A (zh) * 2010-10-18 2018-01-19 大日本住友制药株式会社 注射用缓释制剂
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
WO2012090138A1 (en) 2010-12-27 2012-07-05 Ranbaxy Laboratories Limited Processes for the preparation of iloperidone
CN102680636A (zh) * 2011-03-11 2012-09-19 天津药物研究院 一种伊潘立酮原料药及其中间体的质量控制方法
NZ627778A (en) 2012-01-26 2017-01-27 Inotek Pharmaceuticals Corp Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
CA3159064A1 (en) 2012-01-26 2013-08-01 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CN102633786B (zh) * 2012-04-18 2013-11-27 吉林三善恩科技开发有限公司 一种伊潘立酮药物共晶及其制备方法
CN102659771B (zh) * 2012-04-18 2013-11-27 吉林三善恩科技开发有限公司 一种伊潘立酮药物共晶及其制备方法
CA2872324C (en) 2012-05-18 2017-06-06 Vanda Pharmaceuticals Inc. Metabolites of (1r-trans)-n-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
WO2014100292A1 (en) 2012-12-18 2014-06-26 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
SG11201506882YA (en) 2013-03-15 2015-09-29 Inotek Pharmaceuticals Corp Ophthalmic formulations
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
CN103599074A (zh) * 2013-11-26 2014-02-26 重庆医药工业研究院有限责任公司 一种伊潘立酮缓释微球及其制备方法
BR112017017608A2 (pt) 2015-02-17 2018-05-08 Vanda Pharmaceuticals Inc métodos para tratamento de esquizofrenia ou um sintoma de esquizofrenia, para prevenir uma recaída esquizofrênica e para manter o efeito de iloperidona para esquizofrenia.
US11071728B2 (en) 2015-12-11 2021-07-27 Vanda Pharmaceuticals Inc. Treatment of schizophrenia
CN106831741B (zh) * 2016-12-28 2019-08-23 北京医药集团有限责任公司 一种伊潘立酮超细粉体的制备方法
US10935106B2 (en) * 2018-06-14 2021-03-02 Serapid, Inc. Block chain with monolithic links
US20200171018A1 (en) * 2018-12-04 2020-06-04 Vanda Pharmaceuticals Inc. Depot administration of iloperidone
CN113164382A (zh) * 2018-12-04 2021-07-23 万达制药公司 伊潘立酮的贮库施用
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB216416A (en) 1923-09-06 1924-05-29 James Baker And Sons Ltd Improvements in boots and shoes
JPS53108940A (en) * 1976-10-28 1978-09-22 Hoechst France Optically active nncarbethoxyyalphaa aminophenyl acetic acids * its preparation and its use for preparation of optically active alpha aminoophenylacetic acid
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
DE3345355A1 (de) * 1983-12-15 1985-06-27 Hoechst Ag, 6230 Frankfurt Verfahren zur racematspaltung bicyclischer imino-(alpha)-carbonsaeureester
DE3511587A1 (de) * 1985-03-27 1986-10-02 Schering AG, Berlin und Bergkamen, 1000 Berlin Glykoester des estradiols und estriols
US4886370A (en) 1987-08-25 1989-12-12 Nkk Corporation Method for detecting a state of substance existing in pipe
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5364866A (en) 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
DE69021645T2 (de) * 1989-05-19 1996-02-22 Hoechst Roussel Pharma N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
ATE149523T1 (de) * 1990-06-04 1997-03-15 Schering Corp Verfahren zur herstellung von interferon-alpha-2 kristallen
ZA933134B (en) * 1992-05-08 1993-11-30 Akzo Nv Depot preparation
CA2148823C (en) 1992-11-17 1999-03-09 Welfide Corporation Sustained release microsphere preparation containing antipsychotic drug and production process thereof
SI0729357T1 (en) 1993-11-19 2005-06-30 Janssen Pharmaceutica N.V. Microencapsulated 1,2-benzazoles
US5902882A (en) * 1996-04-17 1999-05-11 Hoffmann-La Roche Inc. Assymetric synthesis of azepines
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
EP0984968A1 (de) * 1997-05-26 2000-03-15 Akzo Nobel N.V. Salze von aromatischen sufonsäuren
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
DE19816070A1 (de) 1998-04-09 1999-10-14 Aventis Res & Tech Gmbh & Co Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
CA2345767A1 (en) 1998-10-16 2000-04-27 Paul Leonce Irma De Nijs Therapy for improving cognition
US6509310B1 (en) 2000-06-01 2003-01-21 Huish Detergents, Inc. Compositions containing α-sulfofatty acid esters and method of making the same
EP1290024A1 (de) 2000-06-02 2003-03-12 Novo Nordisk A/S Glukose-abhängige freisetzung von insulin aus glukose-erfassenden insulinderivaten
JP2005504783A (ja) * 2001-08-31 2005-02-17 ノバルティス アクチエンゲゼルシャフト イロペリドン代謝産物の光学異性体
DE60238780D1 (de) * 2001-10-30 2011-02-10 Novartis Ag Depot formulierungen von iloperidone und einem sternförmigen polymer
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
ZA200410323B (en) 2006-06-28
US8227488B2 (en) 2012-07-24
US8293765B2 (en) 2012-10-23
JP5392961B2 (ja) 2014-01-22
PT1523335E (pt) 2007-02-28
CY1106305T1 (el) 2011-10-12
DK1523335T3 (da) 2007-01-29
JP5670698B2 (ja) 2015-02-18
EP1523335B1 (de) 2006-12-20
US20050250813A1 (en) 2005-11-10
NZ537598A (en) 2006-07-28
AU2003281154A1 (en) 2004-02-02
ES2279153T3 (es) 2007-08-16
GB0216416D0 (en) 2002-08-21
HK1076029A1 (en) 2006-01-06
US20090099232A1 (en) 2009-04-16
US20110212141A1 (en) 2011-09-01
DE60310564D1 (de) 2007-02-01
CA2492467A1 (en) 2004-01-22
CA2492467C (en) 2010-03-16
US8614232B2 (en) 2013-12-24
WO2004006886A2 (en) 2004-01-22
JP2011016849A (ja) 2011-01-27
DE60310564T2 (de) 2007-10-04
AU2003281154B2 (en) 2006-10-12
US20120156264A1 (en) 2012-06-21
JP2005533093A (ja) 2005-11-04
WO2004006886A3 (en) 2004-02-19
US20130012542A1 (en) 2013-01-10
EP1523335A2 (de) 2005-04-20

Similar Documents

Publication Publication Date Title
ATE348635T1 (de) Injizierbare depotformulierung enthaltend iloperidonkrystalle
ES2500068T3 (es) Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
CO6311078A2 (es) Compuestos heterociclicos que contienen dos o más heteroanillos, que contienen átomos de nitrogeno como únicos heteroátomos en el anillo, en donde al menos un anillo es de 6 miembros con un átomo de nitrógeno, que contienen tres ó más heteroátomos, c
CO5690130A1 (es) Derivados de eter biarilico que presentan actividad como inhibidores de la recaptacion de monoaminas para el tratamiento del snc
TW200626558A (en) Indazolone derivatives
AR073689A1 (es) Derivados de azaindazol, antagonistas de receptores ccr1, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y de intermediarios, y uso para tratar enfermedades autoinmunes ,diabetes y alzheimer, entre otras.
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
MX2008009705A (es) Composiciones farmaceuticas que contienen docetaxel, un inhibidor de degradacion y un proceso para obtener el mismo.
CO6160299A2 (es) Solvatos cristalinos y complejos de derivados de (1s)-1,5-anhidro-1-c-(3-((fenil)metil)fenil)-d-glucitol con aminoácidos como inhibidores sglt2 para el tratamiento de diabetes.
RU94029662A (ru) Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения
BRPI0707493B8 (pt) composto inibidor de enzimas e1 ativadoras e composição farmacêutica contendo o referido composto
TNSN08022A1 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
AR047928A1 (es) Derivados de tetrahidropiridoindol
DE502005008631D1 (de) Dermatologischen zubereitungen
ATE442847T1 (de) Benzimidazol-derivate als mek-hemmer
CO5231142A1 (es) TIADIAZOLA COMO INGREDIENTE ACTIVO, EN COMBINACIàN CON AL ME NOS UN FUNGICIDA SELECCIONADO DE LOS COMPONENTES QUE TIENE UNA ACTIVIDAD FUNGICIDA CONTRA LAS ENFERMEDADES DE LAS PLAN- TAS Y UN METODO PARA EL USO DEL MISMO
DE602005010886D1 (de) Zusammensetzungen mit trialkanolamin-alkoxylat-puffer
MX2007010881A (es) Composiciones de peroxido de benzoilo y metodos de uso.
AR056586A1 (es) Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
DE60333746D1 (de) Thienylverbindungen
PE20040978A1 (es) Compuestos antiinflamatorios de di y trifluoro-triazolo-piridinas
EA200702029A1 (ru) НОВЫЙ КЛАСС АКТИВАТОРОВ γ;δ Т-КЛЕТОК И ИХ ПРИМЕНЕНИЕ
AR053678A1 (es) Compuestos farmaceuticamente activos, su manufactura, composiciones que los contienen y su uso
BRPI0411265A (pt) métodos para a preparação de composições de polpa de fruta estabilizada e de purê estável

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1523335

Country of ref document: EP